Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also works with proprietary formulation technologies designed to support liquid-stable, ready-to-use injectable medicines and reduce preparation steps for patients and caregivers. Its business is centered on specialty pharmaceuticals that address complex, often long-term conditions in endocrinology, neurology, and related areas, with a focus on patient-friendly delivery formats and commercial therapies already in market.